<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Post-translational modification by SUMO was proposed to modulate the pathogenesis of several <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3/<z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:hpo ids='HP_0002180'>neurodegenerative disease</z:hpo> caused by polyQ-expanded ataxin-3 </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously shown that ataxin-3 was a new target of SUMOylation in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>Here we identified that the major SUMO-1 binding site was located on lysine 166 </plain></SENT>
<SENT sid="4" pm="."><plain>SUMOylation did not influence the subcellular localization, ubiquitination or aggregates formation of mutant-type ataxin-3, but partially increased its stability and the cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Our findings revealed the role of ataxin-3 SUMOylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> pathogenesis </plain></SENT>
</text></document>